Do you know IMAS? If you are a professional in Market Access who believes that your education and training are crucial for patient access to relevant therapies, then you should!

IMAS stands for International Market Access Society. It derives from MAS, the Market Access Society founded in France more than 10 years ago. The very first meeting of IMAS called ACCESS 2023 Miami Beach took place in April 2023. This meeting brought together different key stakeholders and professionals in discussions on the current challenges in market access, pricing and reimbursement.

On day 1 of the conference, the issue panel “Market Access of Rare Diseases – Learning from Current Experience in Oncology and Gene Therapies and Future Perspective” focused on current market access challenges with innovative cell and gene therapies in oncology and rare diseases and potential solutions for enabling patient access. This session moderated by Yoojung Yang, PharmD, MS, Head of North America, HEOR, Vertex Pharmaceuticals involved Lou Garrison, PhD, Professor Emeritus, The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Meriem Bouslouk-Marx, PhD, MSc International Health, G-BA Benefit Assessment Expert, AMNOG Orphan Drug Specialist, MBM Future Health and Samuel Ang, Global Access Lead, Takeda.

Dr. Meriem Bouslouk-Marx presented a paper with the title “New AMNOG Complexities for Orphan Drugs – Gene Therapies in Oncology and Beyond”.

MBM Future Health AMNOG Gene therapies

From left to right: Lou Garrison, Meriem Bouslouk-Marx, Samuel Ang and Yoojung Yang. Photo by © DDJ